Health Care • Medical/Dental Instruments
$1.22 ▼ -0.10
(-7.58%)
MKT CAP: $73.9M • VOL: 2.80M
52W L $0 52W H $4
ROARABLE / RQD
E • 31/100
PIOTROSKI
2 / 9
QTEX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $289.0K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $2.0K | — | — |
| Gross Margin % | 0.7% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$13.6M | -$11.3M | -$12.1M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$13.2M | -$11.1M | -$11.3M |
| EBITDA (Normalized) | -$13.5M | -$11.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$9.9M | -$9.4M | -$9.7M |
| Capital Expenditures (CapEx) | $103.0K | $164.0K | — |
| Free Cash Flow (FCF) | -$10.0M | -$9.5M | -$9.7M |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.2M | $5.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $2.3M | $4.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR QTEX.